Skip to main content
SpringerLink
Log in
Book cover

Neuro-Psychopharmaka Ein Therapie-Handbuch pp 316–334Cite as

Exkurs: Begleitende Behandlung von psychiatrischen Symptomen bei Morbus Parkinson

  • Chapter

  • 93 Accesses

Zusammenfassung

Verhaltensstörungen, Depressionen, isolierte kognitive Störungen, pharmakotoxische Psychosen und schließlich dementive Veränderungen werden in zunehmendem Maße bei Parkinson-Patienten beobachtet und mÜssen bei der Behandlung berÜcksichtigt werden. Zur Zeit James Parkinsons stand die Beurteilung der motorischen StÖrung vÖllig im Vordergrund. HÖhere psychische Funktionen — mit Ausnahme von Depressionen, seltenen sensorischen Mißempfindungen und im Finalstadium auftretende delirante Zustandsbilder — wurden im wesentlichen bis zur EinfÜhrung der modernen Anti-Parkinson-Therapie selten und nur am Rande beschrieben. In den letzten hundert Jahren hat sich die durchschnittliche Lebenserwartung in den Industriestaaten nahezu verdoppelt, und es kam zu einer explosionsartigen Zuwachsrate der Hochbetagten von mehreren 100 bis über 1000% (Rückert 1984).

This is a preview of subscription content, log in via an institution.

Chapter
USD   29.95
Price excludes VAT (USA)
  • Available as PDF
  • Read on any device
  • Instant download
  • Own it forever
eBook
USD   64.99
Price excludes VAT (USA)
  • Available as PDF
  • Read on any device
  • Instant download
  • Own it forever
Softcover Book
USD   84.99
Price excludes VAT (USA)
  • Compact, lightweight edition
  • Dispatched in 3 to 5 business days
  • Free shipping worldwide - see info

Tax calculation will be finalised at checkout

Purchases are for personal use only

Learn about institutional subscriptions

Preview

Unable to display preview. Download preview PDF.

Unable to display preview. Download preview PDF.

Literatur

  • Agid Y, Javoy-Agid F, Ruberg M (1987) Biochemistry of neurotransmitters in Parkinson’s disease. In: Marsden CD, Fahn S (eds) Movement disorders 2. Butterworth, London, pp 166–230

    Google Scholar 

  • Ambrozi L, Danielczyk W (1988) Die Behandlung zerebraler FunktionsstÖrungen mit Memantine bei psychogeriatrischen Patienten — Ergebnisse einer Phase-II-Doppelblindstudie. Pharmacopsychiatry 21: 144–146

    Article  PubMed  CAS  Google Scholar 

  • Andersen J, Aabro E, Gulmann N, Hjelmisted A, Pedersen HE (1980) Anti-depressive treatment in Parkinson’s disease: a controlled trial of the effect of nortriptyline in patients with PD treated with L-dopa. Acta Neurol Scand 62: 210–219

    Article  PubMed  CAS  Google Scholar 

  • Baldessarini RJ, Marsh E (1990) Fluoxetine and side effects [Letter]. Arch Gen Psychiatry 47: 191–192

    Article  PubMed  CAS  Google Scholar 

  • Baldessarini RJ, Frankenburg FR (1991) Clozapine: a novel antipsychotic agent. N Engl J Med 324: 740–754

    Google Scholar 

  • Baldwin RC, Benbow SM, Marriott A, Tomenson B (1993) Depression in old age. A reconsideration of cerebral disease in relation to outcome. Br J Psychiatry 163: 82–90

    Article  PubMed  CAS  Google Scholar 

  • Barbeau A, Mars H, Gillo-Joffroy L (1971) Adverse clinical side effects of levo-dopa therapy. In: Mcdowell FH, Markham CH (eds) Recent advances in Parkinson’s disease. FA Davis, Philadelphia, pp 203–257

    Google Scholar 

  • Barber J, Tomer R, Sroka H, Myslobodsky MS (1985) Does unilateral dopamine deficit contribute to depression? Psychiatr Res 15: 17–24

    Article  CAS  Google Scholar 

  • Beasley BL, Nutt JG, Davenport R W, Chase TN (1980) Treatment with tryptophan of levodopa-associated psychiatric disturbances. Arch Neurol 37: 155–156

    Article  PubMed  CAS  Google Scholar 

  • Ben-Shlomo Y, Marmot MG (1994) Survival and cause of death in Parkinson’s disease: possible clues to aetiology. Clin Neuropharmacol VIII/1: 143

    Google Scholar 

  • Birkmayer W, Riederer P (1980) Die Parkinson-Krankheit: Biochemie, Klinik, Therapie. Springer, Wien New York, S 167

    Google Scholar 

  • Bonner D, Howard R (1995) Treatment-resistant depression in the elederly. Int Psychogeriatr 7 [Suppl]: 83–94

    Article  PubMed  Google Scholar 

  • Booth G (1948) Psychodynamics in parkinsonism. Psychosom Med 10: 1–4

    PubMed  CAS  Google Scholar 

  • Bouchard RH, Pourcher E, Vincent P (1989) Fluoxetine and extrapyramidal side effects (Letters to the editor). Am J Psychiatry 146: 1352–1353

    Google Scholar 

  • Braak H, Braak E, Yilmazer D, de Vos RAI, Jansen ENH, Bohl J (1996) Pattern of brain destruction in Parkinson’s and Alzheimer’s diseases. J Neural Transm 103: 455–490

    Article  PubMed  CAS  Google Scholar 

  • Brannan T, Prikhojan A, Martínez-Tica J, Yahr MD (1995) In vivo comparison of the effects of inhibition of MAO-A versus MAO-B on striatal L-DOPA and dopamine metabolism. J Neural Transm 10: 79–89

    Article  CAS  Google Scholar 

  • Braun R, Jahanshahi M (1995) Depression in Parkinson’s disease: a psychosocial viewpoint. Adv Neurol 65: 61–84

    Google Scholar 

  • Brod TM (1989) Fluoxetine and extrapyramidal side effects (Letters to the editor). Am J Psychiatry 146: 1353

    Google Scholar 

  • Brown GI (1975) Parkinsonism depression and ECT. Am J Psychiatry 132: 1084

    Google Scholar 

  • Brown GL, Wilson WP (1972) Parkinsonism and depression. South Med J 65: 540–545

    Article  PubMed  CAS  Google Scholar 

  • Brown RG, Maccarthy B, Gotham A-M, Der GJ, Marsden CD (1988) Depression and disability in Parkinson’s disease: a follow-up of 132 cases. Psychol Med 18: 49–55

    Article  PubMed  CAS  Google Scholar 

  • Brücke T, Danielczyk W, Simayi M, Sofic E, Riederer P (1986) Terguride: partial dopamine agonist in the treatment of Parkinson’s disease. Adv Neurol 45: 573–576

    Google Scholar 

  • Burke WJ, Peterson J, Rubin EH (1988) Electroconvulsive therapy in the treatment of combined depression and Parkinson’s disease. Psychosomatics 29: 341–346

    Article  PubMed  CAS  Google Scholar 

  • Caley CF, Friedmann JH (1992) Does fluoxetine exacerbate Parkinson’s disease? J Clin Psychiatry 53: 278–282

    PubMed  CAS  Google Scholar 

  • Candy JM, Perry RH, Perry EK, Irving D, Blessed G, Fairbairn AF, Tomlinson BE (1983) Pathological changes in the nucleus of Meynert in Alzheimer’s disease and Parkinson’s disease. J Neurol Sci 54: 277–289

    Article  Google Scholar 

  • Carlsson M, Carlsson A (1990) Interactions between glutamatergic and monoaminergic systems within the basal ganglia — implications for schizophrenia and Parkinson’s disease. Trends Neurosci 13: 272–276

    Article  PubMed  CAS  Google Scholar 

  • Casey DE (1989) Clozapine: neuroleptic-induced EPS and tardive dyskinesia. Psychopharmacology 99: 47–53

    Article  Google Scholar 

  • Celesia GG, Barr AN (1970) Psychosis and other psychiatric manifestations of levodopa therapy. Arch Neurol 23: 193–200

    Article  PubMed  CAS  Google Scholar 

  • Celesia CG, Wannamaker WM (1972) Psychiatric disturbances in Parkinson’s disease. Dis Nerv Syst 33: 577–583

    PubMed  CAS  Google Scholar 

  • Cooper JA, Sagar H, Doherty SM, Jordan N, Tidswell P, Sullivan EV (1992) Different effects of dopaminergic and anticholinergic therapies on cognitive and motor function in Parkinson’s disease. A follow-up study of untreated patients. Brain 115: 1701–1725

    Article  PubMed  Google Scholar 

  • Cotzias GC, Papavasiliou PS, Gellene R (1969) Moditication of parkinsonism. Chronic treatment with 1-dopa. N Engl J Med 280: 337

    Article  PubMed  CAS  Google Scholar 

  • Crow TJ, Johnstone EC, Mcclelland HA (1976) The coincidence of schizophrenia and parkinsonism: some neurochemical implications. Psychol Med 6: 227

    Article  PubMed  CAS  Google Scholar 

  • Crystal H, Dickson D, Lizardi J, Davies P, Wolfson L (1990) Antemortem diagnosis of diffuse Lewy body disease. Neurology 40: 1523–1528

    Article  PubMed  CAS  Google Scholar 

  • Damasio AR, Labo-Antunes J, Macedo C (1971) Psychiatric aspects in parkinsonism treated with 1-dopa. J Neurol Neurosurg Psychiatry 34: 502–507

    Article  PubMed  CAS  Google Scholar 

  • Danielczyk W (1973) Die Behandlung von akinetischen Krisen. Med Welt 24 (NF): 1278–1282

    PubMed  CAS  Google Scholar 

  • Danielczyk W (1978) Akute psychische Störungen während der L-Dopa-Therapie von Parkinsonkranken. In: Fischer PA (Hrsg) Langzeitbehandlung des Parkinson-Syndroms. Schattauer, Stuttgart New York, S 211–218

    Google Scholar 

  • Danielczyk W (1979) Akute pahrmakotoxische Psychosen bei chronischen zerebralen Erkrankungen. Wien Med Wochenschr 129[Suppl 55]: 3–15

    Google Scholar 

  • Danielczyk W (1981) Die Behandlung von phar-makotoxischen Psychosen bei Parkinson-Patienten mit Clopenthixol. Wien Klin Wochenschr 93: 500–501

    PubMed  CAS  Google Scholar 

  • Danielczyk W (1983) Various mental behavioural disorders in Parkinson’s disease, primary degenerative senile dementia, and multi infarction dementia. J Neural Transm 56: 161–176

    Article  PubMed  CAS  Google Scholar 

  • Danielczyk W (1986) Akinetische Krisen, akinetische Endzustände und Sterbealter bei hospitalisierten Parkinson-Patienten. In: Fischer PA (Hrsg) Spätsyndrome der Parkinson-Krankheit. Editiones Roche, Basel, S 89–98

    Google Scholar 

  • Danielczyk W, Fischer P (1989) Parkinson’s disease: development of dementia in aging. In: Przuntek H, Riederer P (eds) Early diagnosis and preventive therapy in Parkinson’s disease. Springer, Wien New York, pp 9–17

    Chapter  Google Scholar 

  • Danielczyk W, Fischer P (1990a) Psychiatric complications and shift of death age in Parkinson’s disease. Adv Neurol 53: 405–410

    PubMed  CAS  Google Scholar 

  • Danielczyk W, Fischer P (1990b) Neuroleptische Therapie bei Morbus Parkinson. In: Müller-Oerlinghausen B, Möller H-J, Rüther E (Hrsg) Thioxanthene in der neuroleptischen Behandlung. Springer, Berlin Heidelberg New York Tokyo, S 137–142

    Google Scholar 

  • Danielczyk W, Fischer P, Laussegger C (1988) Antiparkinson-Therapie und Psychopharmaka. AuslÖsung von Psychosen durch Dosissteigerungen und medikamentÖse Wechselwirkungen. In: Fischer PA (Hrsg) Modifizierende Faktoren bei der Parkinson-Therapie. Editiones Roche, Basel, S 187–200

    Google Scholar 

  • Danielczyk W, Simanyi M, Fischer P, Streifler M, Jellinger K (1989) Der differentialdiagnostische Wert des EEG im Verlauf von SDAT, MID und schwerer Depression im Alter. Forum Medizin, Gerontopsychiatrie: 245–264

    Google Scholar 

  • Desmet Y, Ruberg M, Serdau M, Dubois B, Lhermitte F, Agid Y (1982) Confusion, dementia and anticholinergics in Parkinson’s disease. J Neurol Neurosurg Psychiatry 45: 1161–1164

    Article  CAS  Google Scholar 

  • Dingemanse J (1993) An update of recent moclobemide interaction data. Int Clin Psychopharmacol 7: 167–180

    Article  PubMed  CAS  Google Scholar 

  • Doonief G, Mirabello E, Bell K, Marder K, Stern Y, Mayeux R (1992) An estimate of the incidence of depression in idiopathic Parkinson’s disease. Arch Neurol 49: 305–307

    Article  Google Scholar 

  • Douyon R, Serby M, Klutchko B, Rotrosen J (1989) ECT and Parkinson’s disease revisited: a „naturalistic“ study. Am J Psychiatry 146: 1451–1455

    PubMed  CAS  Google Scholar 

  • Dovenmuehle R H, Verwoerdt A (1963) Physical illness and depressive symptomatology. II. Factors of length and severity of illness and frequency of hospitalization. J Am Geriatr Soc 18: 260

    CAS  Google Scholar 

  • Dray A (1981) Serotonin in the basal ganglia: functions and interactions with other neuronal pathways. J Physiol Paris 77: 393–403

    PubMed  CAS  Google Scholar 

  • Dubois B, Ruberg M, Javoy-Agid F, Ploska A, Agid Y (1983) A subcortical-cortical cholinergic system is affected in Parkinson’s disease. Brain Res 288: 213–218

    Article  PubMed  CAS  Google Scholar 

  • Dubois B, Danze F, Pillon B, Cusimano G, Lhermitte F, Agid Y (1987) Cholinergic-dependent cognitive deficits in Parkinson’s disease. Ann Neurol 22: 26–30

    Article  PubMed  CAS  Google Scholar 

  • Dubois B, Defontaines B, Deweer B, Malapani C, Pillon B (1995) Cognitive and behavioral changes in patients with focal lesions of the basal ganglia. Adv Neurol 65: 29–41

    PubMed  CAS  Google Scholar 

  • Ebmeier K, Calder S, Crawford J, Stewart L, Besson J, Mutch W (1990) Clinical features predicting dementia in idiopathic Parkinson’s disease: a follow-up study. Neurology 40: 1222–1224

    Article  PubMed  CAS  Google Scholar 

  • Factor SA, Singer C (1992) Neuroleptic malignant syndrome. In: Lang AE, Weiner WJ (eds) Drug-induced movement disorders. Futura, Mount Kisco, pp 199–230

    Google Scholar 

  • Factor SA, Brown D, Molho ES, Podskalny GD (1994) Clozapine: a two year open trial in Parkinson’s disease patients with psychosis. Neurology 44: 544–546

    Article  PubMed  CAS  Google Scholar 

  • Factor SA, Molho ES, Podskalny GD, Brown D (1995) Parkinson’s disease: drug-induced psychiatric states. Adv Neurol 65: 115–138

    PubMed  CAS  Google Scholar 

  • Fahn S, Snider S, Prasad ALN, Lane E, Makadon H (1975) Normalization of brain serotonin by L-tryptophan in levodopa treated rats. Neurology 25: 861–865

    Article  PubMed  CAS  Google Scholar 

  • Fall P-A, Ekman R, Granérus A-K, Thorell L-H, Wålinder J (1995) ECT in Parkinson’s disease. Changes in motor symptoms, monoamine metabolites and neuropeptides. J Neural Transm 10: 129–140

    Article  CAS  Google Scholar 

  • Fibiger HC (1984) The neurogiological substrates of depression in Parkinson’s disease: a hypothesis. Can J Neurol Sci 11: 105–107

    PubMed  CAS  Google Scholar 

  • Fischer PA (1996) Lehrbuch der Gerontopsychiatrie — praktische Gerontopsychiatrie. Enke, Stuttgart

    Google Scholar 

  • Fischer PA, Schneider E, Jacobi P (1982) Depressive Verstimmungen bei Parkinson-Kranken im Langzeitverlauf. In: Fischer PA (Hrsg) Psychopathologie des Parkinson-Syndroms. Editiones Roche, Basel, S 139–152

    Google Scholar 

  • Fischer P, Danielczyes W, Simanyi M, Streifler MB (1990) Dopaminergic psychosis in advanced Parkinson’s disease. Adv Neurol 53: 391–397

    PubMed  CAS  Google Scholar 

  • Förstl H, Besthorn C, Sattel H, Zerfass R, Geiger-Kabisch C Schreiter-Gasser, Hentschel F (1996) Volumetrische Himveränderugen und quantitatives EKG bei normalem Altern und Alzheimer-Demenz. Der Nervenarzt 67: 53–61

    Article  PubMed  Google Scholar 

  • Fras I, Litin EM (1968) Mental symptoms as an aid in the early diagnosis of carcinoma of the pancreas. Gastroenterology 55: 191–198

    PubMed  CAS  Google Scholar 

  • Frazer A Mendels J (1977) Use of 1-dope in depression. Adv Biochem Psychopharmacol 16: 671–675

    PubMed  CAS  Google Scholar 

  • Friedman JH (1991) The management of the levodopa psychoses. Clin Neuropharmacol 14: 283–295

    Article  PubMed  CAS  Google Scholar 

  • Friedman J H, Lannon MC (1989) Clozapine in the treatment of psychosis in Parkinson’s disease. Neurology 39: 1219–1221

    Article  PubMed  CAS  Google Scholar 

  • Fünfgeld EW (1972) Zweijährige Erfahrungen mit der Amantadintherapie bei Parkinsonismus. Ther Woche 39: 3282–3299

    Google Scholar 

  • Fünfgeld EW (1995) Computerised brain electrical activity findings of Parkinson patients suffering from hyperkinetic side effects (hypersensitive dopamine syndrome) and a review of possible sources. J Neural Transm [Suppl 46]: 347–361

    Google Scholar 

  • Fünfgeld KW, Zwischenbrugger H (1994) Hinweise auf eine cerebro-toxische Wirkung von hohen Dopa-Dosen bei der Parkinson-Krankheit. In: Huffmann G, Braune HJ, Henn KH (Hrsg) Extrapyramidalmotorische Erkrankungen. Einhorn Presse Verlag, S 344–349

    Google Scholar 

  • Garcia C, Reding M, Blass J (1981) Overdiagnosis of dementia. J Am Geriatr Soc 29: 407–410

    PubMed  CAS  Google Scholar 

  • Gerlach J, Ahlfors UG, Amthor KF, Dencker SJ, Gravem A (1986) Effect of different neuroleptics in tardive dyskinesia and parkinsonism. Psychopharmacology 90: 423–429

    Google Scholar 

  • Goldstein M, Lew JY, Hata F, Lieberman A (1978) Binding interactions of ergot alkaloids with monoaminergic receptors in the brain. Gerontology 25[Suppl I]: 76–85

    Article  Google Scholar 

  • Goodwin FK (1971a) Behavioral effects of 1-dopa in man. Sem Psychiatry 3: 477–492

    CAS  Google Scholar 

  • Goodwin FK (1971b) Psychiatric side effects of levodopa in man. JAMA 218: 1915–1920

    Article  PubMed  CAS  Google Scholar 

  • Gotham AM, Brown R G, Marsden CD (1988) Depression in Parkinson’s disease: a qualitative and quantitative analysis. J Neurol Neurosurg Psychiatry 49: 381–389

    Article  Google Scholar 

  • Götz ME, Fischer P, Gsell W, Riederer P, Streifler M, Simanyi M, Müller F, Danielczyk W (1995) Platelet monoamine oxidase B activity in dementia: a 4 year follow-up. J Neural Transm [Gen Sect] 102: XVII

    Google Scholar 

  • Granérus AK, Axelsson O, Fall P A, Fredriksson M, Hansson G, Lindvale B, Olsson JE (1994) High age at onset indication of low risk for Parkinson’s disease? Clin Neuropharmacol VIII/1: 119–120

    Google Scholar 

  • Greene P, Cote L, Fahn S (1993) Treatment of drug-induced psychosis in Parkinson’s disease with clozapine. Adv Neurol 60: 703–706

    PubMed  CAS  Google Scholar 

  • Growdon JH, Corkin S, Rosen TJ (1990) Distinctive aspects of cognitive dysfunction in Parkinson’s disease. Adv Neurol 53: 365–376

    PubMed  CAS  Google Scholar 

  • Heinrich K, Tegeler J (1983) Dyskognitive, apathische und extrapyramidale Syndrome bei Langzeit-Neurolepsie. In: Hippius H, Klein HE (Hrsg) Therapie mit Neuroleptika. Perimed, Erlangen

    Google Scholar 

  • Herrschaft H (1992) Piracetam. In: Riederer P, Laux G, Pöldinger W (Hrsg) Neuro-Psychopharmaka, Bd 5. Parkinsonmittel und Nootropika. Springer, Wien New York, S 189–200

    Google Scholar 

  • Hershey L, Feldman B, Kim K, Commichau C, Lichter D (1991) Tremor at onset. Arch Neurol 48: 1049–1051

    Article  PubMed  CAS  Google Scholar 

  • Hoehn MM, Yahr MD (1967) Parkinsonism: onset, progression and mortality. Neurology 17: 427–442

    Article  PubMed  CAS  Google Scholar 

  • Hofman A, Shulte W, Tanja T, van Duijn CM, Haaxma R, Lameris AJ, Otten VM, Saan RJ (1989) History of dementia and Parkinson’s disease in 1 st-degree relatives of patients with Alzheimer disease. Neurology 39: 1589–1592

    Article  PubMed  CAS  Google Scholar 

  • Hubble JP, Koller WC (1995) The Parkinsonian personality. Adv Neurol 65: 43–48

    PubMed  CAS  Google Scholar 

  • Huber SJ, Freidenberg DL, Shuttleworth EC, Paulson GW, Clapp LE (1989) Neuropsychological similarities in lateralized parkinsonism. Cortex 25: 461–470

    PubMed  CAS  Google Scholar 

  • Hughes AJ, Daniel SE, Kilford L, Lees AJ (1992) Accuracy of clinical diagnosis of idiopathic Parkinson’s disease: a clinico-pathological study of 100 cases. J Neurol Neurosurg Psychiatry 55: 181–184

    Article  PubMed  CAS  Google Scholar 

  • Iverson S (1984) Cortical monoamines and behavior. In: Descarries L, Reader LA, Jasper HH (eds) Monoamine innervation of the cerebral cortex. Alan Liss, New York, p 349

    Google Scholar 

  • Jackson JA, Free GBM, Pike HV (1923) The psychic manifestations in paralysis agitans. Arch Neurol Psychiatry 10: 680–684

    Article  Google Scholar 

  • Jellinger KA, Bancher CH (1995) Structural basis of mental impairment in Parkinson’s disease. Neuropsychiatrie 9/1: 9–13

    Google Scholar 

  • Jenkins RB, Groh RH (1970) Mental symptoms in parkinsonian patients with L-dopa. Lancet ii: 177–180

    Article  Google Scholar 

  • Joborn C, Hetta J, Palmer M, Akerström G, Ljunghall S (1986) Psychiatric symptomatology in patients with primary hyperparathyroidism. Up J Med Sci 91: 77–87

    Article  CAS  Google Scholar 

  • Jouvent R, Abensour P, Bonnet AM, Widlocher D, Agid Y, Lhermitte F (1983) Antiparkinsonian and anti-depressant effects of high doses of bromocriptine: an independent comparison. J Affect Disord 5: 141–145

    Article  PubMed  CAS  Google Scholar 

  • Keyser DL, Rodnitzky RL (1991) Neuroleptic malignant syndrome in Parkinson’s dease after withdrawal or alteration of dopaminergic therapy. Arch Intern Med 151: 794–796

    Article  PubMed  CAS  Google Scholar 

  • Klawans HL, Goetz CG, Nausieda PA, Weiner WJ (1977) Levodopa-induced dopamine receptor hypersensitivity. Ann Neurol 2: 125–129

    Article  Google Scholar 

  • Koller W (1984) Disturbances of recent memory function in parkinsonian patients on anticholinergic therapy. Cortex 20: 307–311

    PubMed  CAS  Google Scholar 

  • Kornhuber J, Weller M (1994) Neuroleptic malignant syndrome. Curr Opin Neurol 7: 353–357

    Article  PubMed  CAS  Google Scholar 

  • Kornhuber J, Weller M, Riederer P (1993) Glutamate receptor antagonists for neuroleptic malignant syndrome and akinetic hyperthermic Parkinsonian crisis. J Neural Transm 6: 63–72

    Article  CAS  Google Scholar 

  • Kornhuber J, Quack G, Danysz W, Jellinger K, Danielczyk W, Gsell W, Riederer W (1995) Therapeutic brain concentration of the NMDA receptor antagonist amantadine. Neuropharmacology 34/7: 713–721

    Article  Google Scholar 

  • Korsgaard S, Noring U, Povlsen UJ, Gerlach J (1986) Effects of Citalopram, a specific serotonin uptake inhibitor, in tardive dyskinesia and parkinsonism. Clin Neuropharmacol 9: 52–57

    Article  PubMed  CAS  Google Scholar 

  • Kostic VS, Filipovic SR, Lesic D, Momcilovic D, Sokic D, Sternic N (1994) Effect of age at onset on frequency of depression in Parkinson’s disease. J Neurol Neurosurg Psychiatry 57: 1265–1267

    Article  PubMed  CAS  Google Scholar 

  • Kurlan R, Dimitsopulos T (1992) Selegiline and manic behavior in Parkinson’s disease. Arch Neurol 49: 1231

    Article  PubMed  CAS  Google Scholar 

  • Kurland L (1958) Epidemiology: incidence, geographic distribution and genetic considerations. In: Field W (ed) Pathogenesis and treatment of parkinsonism. Charles C Thomas, Springfield, pp 5–43

    Google Scholar 

  • Laitinen L (1969) Desipramine in the treatment of Parkinson’s disease. Acta Neurol Scand 45: 109–113

    Article  PubMed  CAS  Google Scholar 

  • Lange KW (1999) Cognitive functions in Parkinson’s disease. J Neural Transm 106/1: XXI

    Google Scholar 

  • Leonard BE (1993) The comparative pharmacology of new antidepressants. J Clin Psychiatry 54: 3–15

    PubMed  Google Scholar 

  • Lesser RP, Fahn S, Snider SR, Cote LJ, Isgreen WP, Barrett RE (1979) Analysis of the clinical problems in parkinsonism and the complications of long-term levodopa therapy. Neurology 29: 1253–1260

    Article  PubMed  CAS  Google Scholar 

  • Levin BE, Katzen HL (1995) Early cognitive changes and nondementing behavioral abnormalities in Parkinson’s disease. Adv Neurol 65: 85–95

    PubMed  CAS  Google Scholar 

  • Levin BE, Llabre MM, Reisman S (1991) A retrospective analysis of the effects of anticholinergic medication on memory performance in Parkinson’s disease. J Neuropsychiatry Clin Neurosci 3: 412–416

    PubMed  CAS  Google Scholar 

  • Mahieux F, Fénelon G, Flahault A, Manifacier MJ, Michelet D, Boller F (1998) Neuropsychological prediction of dementia in Parkinson’s disease. J Neurol Neurosurg Psychiatry 64: 178–183

    Article  PubMed  CAS  Google Scholar 

  • Marder K, Flood P, Cote L, Mayeux R (1990) A pilot study of risk factors for dementia in Parkinson’s disease. Mov Disord 5: 156–161

    Article  PubMed  CAS  Google Scholar 

  • Marsh CG, Markham CH (1973) Does levodopa alter depression and psychopathology in parkinsonism patients? J Neurol Neurosurg Psychiatry 36: 925–935

    Article  PubMed  CAS  Google Scholar 

  • Maritila RJ, Kuopio AM, Rinne UK (1994) Survival in Parkinson’s disease: early levodopa treatment enhances life expectancy. Clin Neuropharmacol VIII/1: 120–121

    Google Scholar 

  • Mayberg HS, Solomon DH (1995) Depression in Parkinson’s disease: a biochemical and organic viewpoint. Adv Neurol 65: 49–60

    PubMed  CAS  Google Scholar 

  • Mayberg HS, Starkstein SE, Sadzot IB, Preziosi T, Andrezejewski PL, Dannals RF, Wagner HN Jr, Robinson RG (1990) Selective hypometabolism in the inferior frontal lobe in depressed patients with Parkinson’s disease. Ann Neurol 28: 57–64

    Article  PubMed  CAS  Google Scholar 

  • Mayeux R, Stern Y, Rosen J, Leventhal J (1981) Depression, intellectual impairment, and Parkinson disease. Neurology 31: 645–650

    Article  PubMed  CAS  Google Scholar 

  • Mayeux R, Stern Y, Cote L, Williams JBW (1984) Altered serotonin metabolism in depressed patients with Parkinson’s disease. Neurology 34: 642–646

    Article  PubMed  CAS  Google Scholar 

  • Mayeux R, Denaro J, Hemenegildo N, Marder K, Tang MX, Cote LJ, Stern Y (1992) A population-based investigation of Parkinson’s disease with and without dementia. Arch Neurol 49: 492–497

    Article  PubMed  CAS  Google Scholar 

  • Mccance-Katz EF, Marek KL, Price LH (1992) Serotonergic dysfunction in depression associated with Parkinson’s disease. Neurology 42: 1813–1814

    Article  PubMed  CAS  Google Scholar 

  • Melamed E, Zoldan J, Friedberg G, Goldberg-Stein H (1993) Is hallucinosis in Parkinson’s disease due to central serotonergic hyperactivity? Mov Disord 8: 406–407

    Google Scholar 

  • Meltzer HY, Young M, Metz J, Fang VS, Schyve PM, Arora RC (1979) Extrapyramidal side effects and increased serum prolactin following fluoxetine, a new antidepressant. J Neural Transm 45: 165–175

    Article  PubMed  CAS  Google Scholar 

  • Mendlewicz J, Yahr F, Yahr MD (1976) Psychiatric disorders in Parkinson’s disease treated with 1-dopa: a genetic study. Editiones Roche, Basel, p 103 (Adv Parkinsonism)

    Google Scholar 

  • Menza MA, Golbe LI, Codi RA, Forman NE (1993) Dopamine-related personality traits in Parkinson’s disease. Neurology 43: 505–508

    Article  PubMed  CAS  Google Scholar 

  • Mindham RHS (1970) Psychiatric symptoms in parkinsonism. J Neurol Neurosurg Psychiatry 33: 188–191

    Article  PubMed  CAS  Google Scholar 

  • Mitscherlich M (i960) The psychic state of patients suffering from parkinsonism. Karger, Basel, pp 317–324 (Adv Psychosom Med)

    Google Scholar 

  • Mortimer JA, Christensen KJ, Webster DD (1985) Parkinsonian dementia. In: Frederiks JAM (ed) Handbook of clinical neurology 2 (46): neurobehavioral disorders. Elsevier, New York, pp 371–384

    Google Scholar 

  • Muller SR, Dastoor DP, Klinger A, Boillat J (1979) Amantadine in senile dementia: electroencephalographic and clinical effects. J Am Geriatr Soc 27: 9–16

    PubMed  CAS  Google Scholar 

  • Mundinger F, Wünsch F (1980) 7-Jahres-Langzeitergebnisse der stereotaktischen Tremorbehandlung beim Parkinson-Syndrom. In: Fischer PA (Hrsg) Parkinson-Syndrom: Kombinations-und Begleittherapien. Fischer, Stuttgart New York, S 199–209

    Google Scholar 

  • Naber D, Leppig M, Grohmann R, Hippius H (1989) Efficacy and adverse effects of clozapine in the treatment of schizophrenia and tardive dyskinesia — a retrospective study of 387 patients. Psychopharmacology 99: 73–76

    Article  Google Scholar 

  • Nahmias C, Garnett ES, Firnau G, Lang A (1985) Striatal dopamine distribution in parkinsonian patients during life. J Neurol Sci 69: 223–230

    Article  PubMed  CAS  Google Scholar 

  • Nausieda PA, Weiner WJ, Kaplan LR, Weber S, Klawans HL (1982) Sleep disruption in the course of chronic levodopa therapy: an early feature of the levodopa psychosis. Clin Neuropharmacol 5: 183–194

    Article  PubMed  CAS  Google Scholar 

  • Ng LKY, Chase TN, Colburn RW, Kopin IJ (1972) Release of 3H-dopamine by L-5-hydroxytryptophan. Brain Res 45: 499–505

    Article  PubMed  CAS  Google Scholar 

  • Nies A, Robinson DS, Friedman MJ, Green R, Cooper TB, Ravaris CL, Ives JO (1977) Relationship between age and tricyclic antidepressant plasma levels. Am J Psychiatry 134: 790–793

    PubMed  CAS  Google Scholar 

  • Olichneyj M, Douglas G, Corey-Bloom J, Thal LJ (1995) The spectrum of diseases with diffuse lewy bodies. Adv Neurol 65: 159–170

    Google Scholar 

  • Paulus W, Jellinger K (1991) The neurpathologic basis of different clinical subgroups of Parkinson’s disease. J Neuropathol Exp Neurol 50: 743–755

    Article  PubMed  CAS  Google Scholar 

  • Peuch A (1993) Contributions of pharmacology in the treatment of resistance to antidepressive agents. Encephale 19: 407–412

    Google Scholar 

  • Pillhatsch K (1995) Korrelation des organischen Psychosyndroms im Alter mit apparativen Befunden — Aussagekraft von EKG und CCT bei psychiatrischen Erkrankungen im Alter. 2 Gerontol 18: 330–336

    Google Scholar 

  • Poewe W, Karamat E, Kemmler G W, Gerstenbrand F (1990) The premorbid personality of patients with Parkinson’s disease: a comparative study with healthy controls and patients with essential tremor. Adv Neurol 53: 339–342

    PubMed  CAS  Google Scholar 

  • Post F (1962) The significance of affective symptoms in old age [Maudsley Monograph 10]. Oxford University Press, London

    Google Scholar 

  • Prick JJG (1966) Genuine parkinsonism. A psychosomatic, anthropological-psychiatric approach. Abs Work Congress of Psychiatry Madrid, Sandorama Special Number IV

    Google Scholar 

  • Rajput A, Offord K, Beard C, Kurland L (1984) Epidemiology of parkinsonism: incidence, classification and mortality. Ann Neurol 16: 278–283

    Article  PubMed  CAS  Google Scholar 

  • Rajput AH, Uitti RJ, Ho M, Offord K, Rajput A, Basran P (1994) Current survival profile in parkinsonism. Clin Neuropharmacol VIII/1: 121–122

    Google Scholar 

  • Riederer P, Lange KW, Kornhuber J, Danielczyk W (1992) Glutamatergic-dopaminergic balance in the brain. Arzneimittelforschung/Drug Res 42(I), 2a: 265–268

    CAS  Google Scholar 

  • Robins AH (1986) Depression in patients with parkinsonism. Br J Psychiatry 128: 141–145

    Article  Google Scholar 

  • Ruggieri S, Fabbrini G, Bramante L, DePandis, Stocchi, Barbanti P, Vacca L, Manfredi M (1996) An open study with reversible MAO-A inhibitors in complicated Parkinson’s disease. Adv Neurol 69: 595–598

    PubMed  CAS  Google Scholar 

  • Russ M, Fischer PA (1994) Sind die kognitiven Störungen des Parkinson-Kranken „dopaminerg“? In: Fischer PA (Hrsg) Parkinson-Krankheit, Bedeutung nichtdopaminerger FunktionsstÖrungen. Editiones Roche, Basel, S 133–153

    Google Scholar 

  • Rückert W (1984) BevÖlkerungsentwicklung und Altenhilfe von der Kaiserzeit bis zum Jahre 2000. Kuratorium Deutsche Altenhilfe, KÖln, S 98

    Google Scholar 

  • Sadah M, Braham J, Madan M (1982) Effects of anticholinergic drugs on memory in Parkinson’s disease. Arch Neurol 39: 666–667

    Article  Google Scholar 

  • Santamaria J, Tolosa E, Valles A (1986) Parkinson’s disease with depression: a possible subgroup of idipathic parkinsonism. Neurology 36: 1130–1133

    Article  PubMed  CAS  Google Scholar 

  • Schneider E (1999) Therapy of depression and pharmacotoxic psychosis. J Neural Transm 106/1: XXX

    Google Scholar 

  • Schneider E, Fischer PA, Jacobi P, Grotz A (1984) Exogene Psychosen beim Parkinson-Syndrom. Häufigkeit und Entstehungsbedingungen. Fortschr Neurol Psychiat 52: 207–214

    Article  CAS  Google Scholar 

  • Schoenberg B, Anderson D, Haerer A (1985) Prevalence of Parkinson’s disease in the biracial population of Copiah County, Mississippi. Neurology 35: 841–845

    Article  PubMed  CAS  Google Scholar 

  • Scholz E, Dichgans J (1985) Treatment of drug-induced exogenous psychosis in parkinsonism with clozapine and fluperlapine. Eur Arch Psychiatr Neurol Sci 235: 60–64

    Article  CAS  Google Scholar 

  • Schwab RS, Fabing HD, Prichard JS (1950) Psychiatric symptoms and syndromes in Parkinson’s disease. Am J Psychiatry 107: 901–907

    Google Scholar 

  • Schwab RS, England AC Jr, Poskaner DC (1969) Amantadine in the treatment of Parkinson’s disease. J Am Med Assoc 208: 1168–1170

    Article  CAS  Google Scholar 

  • Siemers ER, Schekhar A, Quaid K, Dickson H (1993) Anxiety and motor performance in Parkinson’s disease. Mov Disord 8: 501–506

    Article  PubMed  CAS  Google Scholar 

  • Spicer KB, Roberts RJ, Le Witt PA (1988) Neuropsychological performance in lateralized parkinsonism. Arch Neurol 45: 429–432

    Article  PubMed  CAS  Google Scholar 

  • Starkstein SE, Berthier ML, Bolduc PL, Preziosi TJ, Robinson RG (1989a) Depression in patients with early versus later onset of Parkinson’s disease. Neurology 39: 1141–1145

    Article  Google Scholar 

  • Starkstein SE, Robinson RG, Honig MA, Parikh RM, Joselyn J, Price TR (1989b) Mood changes after right hemisphere lesions. Br J Psychiatry 155: 79–85

    Article  PubMed  CAS  Google Scholar 

  • Starkstein SE, Bolduc PL, Mayberg HS, Preziosi TJ, Robinson RG (1990a) Cognitive impairments and depression in Parkinson’s disease: a follow-up study. J Neurol Neurosurg Psychiatry 53: 597–602

    Article  PubMed  CAS  Google Scholar 

  • Starkstein SE, Preziosi TJ, Bolduc PL, Robinson RG (1990b) Depression in Parkinson’s disease. J Nerv Ment Dis 178: 21–31

    Article  Google Scholar 

  • Starkstein SE, Mayberg HS, Preziosi TJ, Anrezejewski P, Leiguarda R, Robinson RG (1992) Reliability, validity, and clinical correlates of apathy in Parkinson’s diseases. J Neuropsychiat Clin Neurosci 4: 134–139

    CAS  Google Scholar 

  • Stenager EN, Wermuth L, Stenager E, Boldsen J (1994) Suicide in patients with Parkinson’s disease. An epidemiological study. Acta Psychiatr Scand 90: 70–72

    Article  PubMed  CAS  Google Scholar 

  • Strang RR (1965) Imipramine in the treatment of parkinsonism: a double-blind placebo study. Br J Med 2: 33–34

    Article  CAS  Google Scholar 

  • Strauss WH, Klieser E, Luethke H, Burtscheidt W (1988) Dyscognitive syndrome in neuroleptic therapy. Pharmacopsychiatry 21: 298–299

    Article  PubMed  CAS  Google Scholar 

  • Streifler M, Hait Z (1973) Amantadinderivate bei Parkinsonismus im Blindversuch. Ther Woche 40: 3549–3652

    Google Scholar 

  • Suchowersky O, Devries J (1990) Possible interaction between deprenyl and prozac [Letter]. Can J Neurol Sci 17: 352–353

    PubMed  CAS  Google Scholar 

  • Swanson PD (1994) Drug treatment of Parkinson’s disease: is „polytherapy“ best? J Neurol Neurosurg Psychiatry 57: 401–403

    Article  PubMed  CAS  Google Scholar 

  • Tate JL (1989) Extrapyramidal symptoms in a patient taking haloperidol and fluoxetine. Am J Psychiatry 146: 399–400

    PubMed  CAS  Google Scholar 

  • Tatemichi TK, Sacktor N, Mayeux R (1994) Dementia associated with cerebrovascular disease, other degenerative disease, and metabolic disorders. In: Terry RD, Katzmann R, Slick KL (eds) Alzheimer disease. Raven Press, New York, pp 123–166

    Google Scholar 

  • Tiffany T, Cummings JL (1998) Depression in Parkinson’s disease. Pharmacological characteristics and treatment. Drugs & Aging 12: 55–74

    Article  Google Scholar 

  • Uitti RJ, Tanner CM, Rajput AH, Goetz CG, Klawans HL, Thiessen B (1989) Hypersexuality with antiparkinsonian therapy. Clin Neuropharmacol 12: 375–383

    Article  PubMed  CAS  Google Scholar 

  • Uitti R J, Rajput AH, Ahlskog JE, Offord KP, Ho MM, Prasad M, Rajput A, Basran P (1993) Amantadine treatment is an independent predictor of improved survival in parkinsonism. Can J Neurol Sci 20[Suppl 4]: 235

    Google Scholar 

  • van Tol HHM, Bunzow JR, Guan H-C et al. (1991) Cloning of the gene for a human dopamine D4 receptor with high affinity for the antipsychotic clozapine. Nature 350: 610–614

    Article  PubMed  Google Scholar 

  • Venkateswarlu T, Staley CJ, Neal CD (1990) Zuclopenthixol dihydrochloride in the management of behavioural disorders in elderly demented patients: a dose-ranging study. Int J Geriatr Psychiatry 5: 265–270

    Article  Google Scholar 

  • Vogel HP (1982) Symptoms of depression in Parkinson’s disease. Pharmacopsychiatry 15: 192–196

    Article  CAS  Google Scholar 

  • Warborton JW (1967) Depressive symptoms in Parkinson patients referred for thalamotomy. J Neurol Neurosurg Psychiatry 30: 368–370

    Article  Google Scholar 

  • Wolters ECH, Hurwitz TA, Peppard RF, Calne DB (1989) Clozapine: an antipsychotic agent for Parkinson’s disease? Clin Neuropharmacol 12: 83–90

    Article  PubMed  CAS  Google Scholar 

  • Wong DT, Bymaster FP, Reid LR, et al. (1983) Fluoxetine and two other serotonin uptake inhibitors without affinity for neuronal receptors. Biochem Pharmacol 32: 1287

    Article  PubMed  CAS  Google Scholar 

  • Yahr MD, Duvoisin RC, Scheer MJ, Barrett RE, Hoehn MM (1969) Treatment of parkinsonism with levodopa. Arch Neurol (Chic) 21: 343–354

    Article  CAS  Google Scholar 

  • Yaryura-Tobias JA, Diamond B, Merlis S (1970) Psychiatric manifestations of levodopa. Dis Nerv Syst 31: 60–63

    PubMed  CAS  Google Scholar 

  • Young RC, Alexopoulos GS, Shamoian CA (1985) Dissociation of motor response from mood and cognition in a parkinsonian patient treated with ECT. Biol Psychiatry 20: 566–569

    Article  PubMed  CAS  Google Scholar 

  • Yudofsky SC (1979) Parkinson’s disease, depression, and electroconvulsive therapy: a clinical and neurobiologie synthesis. Compr Psychiatry 20: 579–581

    Article  PubMed  CAS  Google Scholar 

  • Zetusky W, Jankovic J, Pirozzolo F (1985) The heterogeneity of Parkinson’s disease: clinical and prognostic implications. Neurology 35: 1222–1224

    Article  Google Scholar 

  • Zoldan J, Friedberg G, Weizman A, Melamed E (1996) Ondansetron, a 5-HT3 antagonist for visual hallucinations and paranoid delusional disorder associated with chronic L-Dopa therapy in advanced Parkinson’s disease. Adv Neurol 69: 541–544

    PubMed  CAS  Google Scholar 

Download references

Authors
  1. W. Danielczyk
    View author publications

    You can also search for this author in PubMed Google Scholar

Editor information

Editors and Affiliations

  1. Klinische Neurochemie, Klinik und Poliklinik für Psychiatrie und Psychotherapie, Würzburg, Bundesrepublik Deutschland

    Peter Riederer

  2. Bezirkskrankenhaus Gabersee, Wasserburg/Inn, Bundesrepublik Deutschland

    Gerd Laux

  3. Wien, Österreich

    Walter Pöldinger

Rights and permissions

Reprints and permissions

Copyright information

© 1999 Springer-Verlag Wien

About this chapter

Cite this chapter

Danielczyk, W. (1999). Exkurs: Begleitende Behandlung von psychiatrischen Symptomen bei Morbus Parkinson. In: Riederer, P., Laux, G., Pöldinger, W. (eds) Neuro-Psychopharmaka Ein Therapie-Handbuch. Springer, Vienna. https://doi.org/10.1007/978-3-7091-6400-6_34

Download citation

  • DOI: https://doi.org/10.1007/978-3-7091-6400-6_34

  • Publisher Name: Springer, Vienna

  • Print ISBN: 978-3-7091-7315-2

  • Online ISBN: 978-3-7091-6400-6

  • eBook Packages: Springer Book Archive

Publish with us

Policies and ethics

Search

Navigation